Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has given ...

Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...

Earlier BMS lacked microcontrollers, advanced sensors, and data-processing capabilities, meaning they couldn't monitor each cell in detail, estimate State of Charge (SoC) or State of Health (SoH), or ...

Already on track to achieve blockbuster status in its third full year on the market, Bristol Myers Squibb’s cardiomyopathy treatment Camzyos has scored in a trial that could pave the way for it to ...

SAN FRANCISCO—Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. But to hear CEO Chris Boerner, Ph.D., tell it, “business development remains a top priority” for the ...

Long-term alliances in pharma enable strategic resource planning and infrastructure development, supporting diverse therapeutic pipelines and ensuring operational reliability. Integrated research, ...

The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...

Learn the benefits and risks of options and how to start trading options Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Samantha (Sam) Silberstein, CFP®, CSLP®, ...